Delta1 Expression, Cell Cycle Exit, and Commitment to a Specific Secretory Fate Coincide within a Few Hours in the Mouse Intestinal Stem Cell System

The stem cells of the small intestine are multipotent: they give rise, via transit-amplifying cell divisions, to large numbers of columnar absorptive cells mixed with much smaller numbers of three different classes of secretory cells - mucus-secreting goblet cells, hormone-secreting enteroendocrine cells, and bactericide-secreting Paneth cells. Notch signaling is known to control commitment to a secretory fate, but why are the secretory cells such a small fraction of the population, and how does the diversity of secretory cell types arise? Using the mouse as our model organism, we find that secretory cells, and only secretory cells, pass through a phase of strong expression of the Notch ligand Delta1 (Dll1). Onset of this Dll1 expression coincides with a block to further cell division and is followed in much less than a cell cycle time by expression of Neurog3 – a marker of enteroendocrine fate – or Gfi1 – a marker of goblet or Paneth cell fate. By conditional knock-out of Dll1, we confirm that Delta-Notch signaling controls secretory commitment through lateral inhibition. We infer that cells stop dividing as they become committed to a secretory fate, while their neighbors continue dividing, explaining the final excess of absorptive over secretory cells. Our data rule out schemes in which cells first become committed to be secretory, and then diversify through subsequent cell divisions. A simple mathematical model shows how, instead, Notch signaling may simultaneously govern the commitment to be secretory and the choice between alternative modes of secretory differentiation

The Cycad Genotoxin MAM Modulates Brain Cellular Pathways Involved in Neurodegenerative Disease and Cancer in a DNA Damage-Linked Manner

Methylazoxymethanol (MAM), the genotoxic metabolite of the cycad azoxyglucoside cycasin, induces genetic alterations in bacteria, yeast, plants, insects and mammalian cells, but adult nerve cells are thought to be unaffected. We show that the brains of adult C57BL6 wild-type mice treated with a single systemic dose of MAM acetate display DNA damage (O6-methyldeoxyguanosine lesions, O6-mG) that remains constant up to 7 days post-treatment. By contrast, MAM-treated mice lacking a functional gene encoding the DNA repair enzyme O6-mG DNA methyltransferase (MGMT) showed elevated O6-mG DNA damage starting at 48 hours post-treatment. The DNA damage was linked to changes in the expression of genes in cell-signaling pathways associated with cancer, human neurodegenerative disease, and neurodevelopmental disorders. These data are consistent with the established developmental neurotoxic and carcinogenic properties of MAM in rodents. They also support the hypothesis that early-life exposure to MAM-glucoside (cycasin) has an etiological association with a declining, prototypical neurodegenerative disease seen in Guam, Japan, and New Guinea populations that formerly used the neurotoxic cycad plant for food or medicine, or both. These findings suggest environmental genotoxins, specifically MAM, target common pathways involved in neurodegeneration and cancer, the outcome depending on whether the cell can divide (cancer) or not (neurodegeneration). Exposure to MAM-related environmental genotoxins may have relevance to the etiology of related tauopathies, notably, Alzheimer's disease

Mixed emotions: The contribution of alexithymia to the emotional symptoms of autism

It is widely accepted that autism is associated with disordered emotion processing, and in particular, with deficits of emotional reciprocity such as impaired emotion recognition and reduced empathy. However, a close examination of the literature reveals wide heterogeneity within the autistic population with respect to emotional competence. Here we argue that, where observed, emotional impairments are due to alexithymia - a condition that frequently co-occurs with autism - rather than a feature of autism per se. Alexithymia is a condition characterized by a reduced ability to identify and describe one’s own emotion, but which results in reduced empathy and an impaired ability to recognize the emotions of others. We briefly review studies of emotion processing in alexithymia, and in autism, before describing a recent series of studies directly testing this ‘alexithymia hypothesis’. If found to be correct, the alexithymia hypothesis has wide-reaching implications for the study of autism, and how we might best support sub-groups of autistic individuals with, and without, accompanying alexithymia. Finally, we note the presence of elevated rates of alexithymia, and inconsistent reports of emotional impairments, in eating disorders, schizophrenia, substance abuse, Parkinson’s Disease, Multiple Sclerosis, and anxiety disorders. We speculate that examining the contribution of alexithymia to the emotional symptoms of these disorders may bear fruit in the same way that it is starting to do in autism

Social anxiety, fear of negative evaluation and the detection of negative emotion in others.

The present study sought to investigate whether social anxiety is associated with enhanced ability to detect negative emotion in others. Subjects scoring high and low on Fear of Negative Evaluation (FNE) performed two tasks before and after a social threat induction. The first task involved identifying the affect (negative vs neutral) in briefly presented (60 msec) slides of faces. The second involved rating the overall emotion conveyed in brief video clips of an actor and detecting discrepancies in the affect conveyed by the visual and auditory channels of the video. Overall the results suggest that high social anxiety subjects have a bias towards identifying others' emotional expressions as negative in the absence of an enhanced ability to discriminate between different emotional states in others. Implications and limitations of the results are discussed

Facial affect recognition and schizotypy

Aim: Deficits in facial affect recognition are well documented in schizophrenia, and have been associated with reduced social functioning and interpersonal difficulties. The aim of the present study was to test the possibility that facial affect recognition deficits represent an endophenotypic marker of schizophrenia liability by testing this capacity in individuals with the predisposition to symptoms of schizophrenia. Methods: Eight hundred and fortythree psychologically healthy participants completed the Schizotypal Personality Questionnaire of which 28 scoring in the upper 15% (highschizotypy group) and 28 scoring in the lower 15% (low-schizotypy group) completed measures of facial affect identification, facial affect discrimination, facial identity recognition, and a measure of negative affect. Results: After controlling for group differences in negative affect and facial identity recognition, negative (but not positive or disorganized) aspects of schizotypy were found to be significantly associated with reduced facial affect discrimination and facial affect recognition accuracy, and in particular, difficulties with the identification of negative emotions. Conclusions: These results provide limited support for the potential trait status of facial affect recognition deficits in schizophrenia and schizophrenia spectrum disorders, and suggest that these deficits may be particularly associated with the predisposition to negative symptoms of schizophrenia

Sea Ice Modelling

Peer reviewe